Answers are grounded in this paper and cite their sources.
IgA nephropathy (IgAN) is increasingly linked to gut mucosal immune dysregulation, but the associated microbial and metabolic features remain inconsistently characterized. In this multicenter cross-sectional study, fecal samples from 187 participants (100 IgAN, 30 membranous nephropathy, 57 controls) and a replication cohort (96 IgAN, 46 controls) across six tertiary hospitals underwent 16S rRNA sequencing. Controls comprised healthy living kidney donors who passed standard donor screening. Differential abundance analysis was performed for genera and PICRUSt2-predicted pathways. Functional validation included short-chain fatty acid (SCFA) quantification and ex vivo SCFA stimulation of patient-derived B cells. IgAN patients differed from controls in beta diversity ( P = 0.001) but not alpha diversity. Among eight genera and 31 pathways associated with IgAN, Blautia , Ruminococcus gnavus group, and pyruvate metabolism (ko00620) were consistently enriched in IgAN in the replication cohort ( P = 0.008, 0.011, and 0.005, respectively). Blautia abundance positively correlated with blood pressure, serum creatinine, and urine protein-to-creatinine ratio in IgAN ( P < 0.05). Serum lactate ( P < 0.001) and butyrate ( P = 0.017) were elevated in IgAN, and butyrate stimulation increased CCR9 + and decreased IL-10 + B cell proportions ex-vivo ( P < 0.05). These findings suggest a potential role for circulating butyrate in mucosal immune dysregulation in IgAN, mediated through altered B-cell homing and impaired regulatory function.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: